DGAP-News: Fresenius Medical Care AG & Co. KGaA and Joslin Diabetes Center Partner to Improve Health of Patients with Diabetic Kidney Disease

Fresenius Medical Care AG & Co. KGaA and Joslin Diabetes Center Partner to Improve Health of Patients with Diabetic Kidney Disease

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Schlagwort(e):

Sonstiges

Fresenius Medical Care AG & Co. KGaA and Joslin Diabetes Center

Partner to Improve Health of Patients with Diabetic Kidney Disease

15.04.2014 / 08:28

---------------------------------------------------------------------

Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA (the "company"

or "Fresenius Medical Care"; Frankfurt Stock Exchange: FME / New York Stock

Exchange: FMS), the world's largest provider of dialysis products and

services, and Joslin Diabetes Center, Inc., the world's preeminent diabetes

research, clinical care and education organization, announced an agreement

today to jointly develop renal care programs in select Joslin Affiliated

Centers for patients with diabetic kidney disease (DKD).

Fresenius Medical Care and Joslin will jointly develop clinical guidelines

and effective care delivery systems to manage high blood pressure, glucose,

and nutrition in patients with DKD. In addition, the organizations will

help educate patients as they prepare for the possibility of end stage

renal disease (ESRD) and the necessity for dialysis or kidney

transplantation. Fresenius Medical Care and Joslin's multidisciplinary and

coordinated approach to chronic disease management will seek to improve

patient outcomes while reducing unnecessary or lengthy hospitalizations,

drug interactions and overall morbidity and mortality associated with

uncoordinated care.

"Identifying and treating individuals with chronic kidney disease,

especially those with diabetes, as early as possible can help us improve

health outcomes for patients and lower costs for the health care system,"

said Ron Kuerbitz, chief executive officer of Fresenius Medical Care North

America. "But even more exciting is what this research can mean for the

future. We hope that bringing together the world leaders in diabetes

research and kidney care will lay the foundation for future therapeutic

breakthroughs."

"We are excited to partner with Fresenius Medical Care," said John L.

Brooks III, President and CEO of Joslin Diabetes Center. "Kidney disease is

one of the most devastating complications of diabetes. Together with

Fresenius Medical Care we hope to make real progress in improving the care

of patients with DKD."

Chronic kidney disease (CKD) and ESRD combined are estimated to affect more

than 13% of the U.S. population, and diabetes is one of the leading causes

of ESRD. The Centers for Disease Control estimates that one in three adults

in this country will have diabetes by 2050 if today's trends continue.

These alarming statistics underscore the importance of the Fresenius

Medical Care - Joslin collaboration and the development of clinical

guidelines to manage care for patients who have both of these complex,

chronic diseases.

About Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of

products and services for individuals undergoing dialysis because of

chronic kidney failure, a condition that affects more than 2.5 million

individuals worldwide. Through its network of 3,250 dialysis clinics in

North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius

Medical Care provides dialysis treatments for 270,122 patients around the

globe. Fresenius Medical Care is also the world's leading provider of

dialysis products such as hemodialysis machines, dialyzers and related

disposable products. For more information about Fresenius Medical Care,

visit the company's website at www.fmc-ag.com.

About Joslin Diabetes Center

Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes

research, clinical care, education and health and wellness programs on a

global scale. Joslin is dedicated to ensuring that people with diabetes

live long, healthy lives and offers real progress in preventing and curing

diabetes. Joslin is an independent, nonprofit institution affiliated with

Harvard Medical School, and is recognized worldwide for driving innovative

solutions in diabetes prevention, research, education, and care. Our

mission is to prevent, treat and cure diabetes. Our vision is a world free

of diabetes and its complications. For more information, visit

www.joslin.org.

Disclaimer

This release contains forward-looking statements that are subject to

various risks and uncertainties. Actual results could differ materially

from those described in these forward-looking statements due to certain

factors, including changes in business, economic and competitive

conditions, regulatory reforms, foreign exchange rate fluctuations,

uncertainties in litigation or investigative proceedings, and the

availability of financing. These and other risks and uncertainties are

detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the

U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.

KGaA does not undertake any responsibility to update the forward-looking

statements in this release.

Ende der Corporate News

---------------------------------------------------------------------

15.04.2014 Veröffentlichung einer Corporate News/Finanznachricht,

übermittelt durch die DGAP - ein Unternehmen der EQS Group AG.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber

verantwortlich.

Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,

Corporate News/Finanznachrichten und Pressemitteilungen.

Medienarchiv unter http://www.dgap-medientreff.de und

http://www.dgap.de

---------------------------------------------------------------------

Sprache: Deutsch

Unternehmen: Fresenius Medical Care AG & Co. KGaA

Else-Kröner-Straße 1

61352 Bad Homburg

Deutschland

Telefon: +49 (0) 6172- 609 2525

Fax: +49 (0) 6172- 609 2301

E-Mail: ir@fmc-ag.com

Internet: www.fmc-ag.de

ISIN: DE0005785802, DE0005785836,

WKN: 578580, 578583

Indizes: DAX

Börsen: Regulierter Markt in Frankfurt (Prime Standard);

Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,

München, Stuttgart; Terminbörse EUREX; NYSE

Ende der Mitteilung DGAP News-Service

---------------------------------------------------------------------

263240 15.04.2014